[{"data":1,"prerenderedAt":170},["ShallowReactive",2],{"drug-ranolazine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":69,"warnings":79,"renal":80,"monitoring":81,"interactions":82,"review":83,"examples":86,"atc":92,"iran":94,"links":114,"populations":131,"usApproval":165},"ranolazine",1,{"fa":7,"en":8},"رانولازین","Ranolazine","cardiovascular",{"fa":11,"en":12},"ضدآنژین","Antianginal",[14],{"name":15,"market":16},"Ranexa","US",[18,19,7],"ranexa","رانکسا",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-500","tablet","oral","500 mg extended-release tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},500,"mg",false,[16],[32],{"source":33,"section":34},"fda-ranolazine","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-1000","1000 mg extended-release tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},1000,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":57,"notes":60},"std","angina",{"fa":48,"en":49},"آنژین مزمن — ۵۰۰ mg دو بار در روز، تا ۱۰۰۰ mg دو بار","Chronic angina — 500 mg twice daily, up to 1,000 mg twice daily",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":56},2,[58],{"source":33,"section":59},"2.1",[61],{"text":62,"refs":65},{"fa":63,"en":64},"قرص کامل بلعیده شود (نشکند، نجود). با برخی داروها حداکثر دوز کمتر (بخش ۷).","Swallow whole (do not crush, break or chew). Lower maximum with some drugs (section 7).",[66,67],{"source":33,"section":59},{"source":33,"section":68},"2.2",[70],{"id":71,"severity":72,"text":73,"refs":76},"ci","block",{"fa":74,"en":75},"مهارکننده‌های قوی CYP3A (کتوکونازول، کلاریترومایسین)؛ القاکننده‌های CYP3A (ریفامپین، فنوباربیتال، علف چای)؛ سیروز کبد.","Strong CYP3A inhibitors (ketoconazole, clarithromycin); CYP3A inducers (rifampin, phenobarbital, St John’s wort); liver cirrhosis.",[77],{"source":33,"section":78},"4",[],[],[],[],{"status":84,"reviewer":85,"date":85},"unverified",null,[87],{"regimen":45,"formulation":22,"input":88,"expect":91},{"ageYears":89,"weightKg":90},65,75,{"perDose":27,"upperPerDose":39},[93],"C01EB18",{"status":95,"forms":96,"refs":109},"registered",[97,101,105],{"code":98,"en":99,"fa":100},"13980","RANOLASINE 500MG TAB","قرص رانولاسین ۵۰۰ میلی‌گرم",{"code":102,"en":103,"fa":104},"21152","RANOLASINE 750MG TAB","قرص رانولاسین ۷۵۰ میلی‌گرم",{"code":106,"en":107,"fa":108},"53016","RANOLASINE 1000MG TAB","قرص رانولاسین ۱۰۰۰ میلی‌گرم",[110],{"source":111,"section":112,"url":113},"darooyab-generic","G-1866\u002FRanolazine","https:\u002F\u002Fwww.darooyab.ir\u002FG-1866\u002FRanolazine",[115,119,123,126,129],{"kind":116,"url":117,"label":118},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=210188","ANDA210188",{"kind":120,"url":121,"label":122},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d74f3dea-7357-4e9a-be9a-2f498a44108a","FDA Ranolazine ER",{"kind":124,"url":125,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa606015.html",{"kind":127,"url":128,"label":93},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C01EB18",{"kind":130,"url":113,"label":8},"darooyab",{"pregnancy":132,"lactation":141,"pediatric":149,"geriatric":157},{"level":133,"text":134,"quote":137,"refs":138},"caution",{"fa":135,"en":136},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data on ranolazine use in pregnant women to inform any drug-associated risks.",[139],{"source":33,"section":140},"8.1",{"level":133,"text":142,"quote":145,"refs":146},{"fa":143,"en":144},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of ranolazine in human milk, the effects on the breastfed infant, or the effects on milk production.",[147],{"source":33,"section":148},"8.2",{"level":133,"text":150,"quote":153,"refs":154},{"fa":151,"en":152},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness have not been established in pediatric patients.",[155],{"source":33,"section":156},"8.4",{"level":133,"text":158,"quote":161,"refs":162},{"fa":159,"en":160},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease, or other drug therapy.",[163],{"source":33,"section":164},"8.5",{"kind":166,"refs":167,"id":118},"ANDA",[168],{"source":33,"section":169},"SPL approval \u002F marketing category",1792111466880]